The global demand for COVID-19 Therapeutics Market is presumed to reach the market size of nearly USD 74.96 BN by 2030 from USD 33.92 BN in 2022 with a CAGR of 10.42% under the study period 2023 - 2030.
COVID-19 therapeutics refer to the drugs and therapies used for the treatment of COVID-19, the respiratory illness caused by the SARS-CoV-2 virus. COVID-19 therapeutics include antiviral drugs, immunomodulatory drugs, and monoclonal antibodies, among others. The goal of COVID-19 therapeutics is to reduce the severity of symptoms, prevent complications, and improve the overall outcomes of patients with COVID-19.
The COVID-19 pandemic has resulted in high demand for COVID-19 therapeutics due to the increasing number of cases and the need for effective treatment options. Governments worldwide are providing funding and support to accelerate the development and availability of COVID-19 therapeutics. This has led to increased investment in research and development, as well as regulatory support for the expedited approval of potential therapies. The emergence of new variants has led to an increased need for COVID-19 therapeutics that can effectively treat these new strains of the virus. New therapeutic targets are being identified as the scientific community learns more about COVID-19, leading to the development of novel therapies that may be more effective in treating the disease. Collaboration among healthcare organizations, including pharmaceutical companies and research institutions, is driving the development and availability of COVID-19 therapeutics.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of covid-19 therapeutics. The growth and trends of covid-19 therapeutics industry provide a holistic approach to this study.
This section of the covid-19 therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Drug Class
By Route Of Administration
By Distribution Channel
This section covers the regional outlook, which accentuates current and future demand for the COVID-19 Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the covid-19 therapeutics market include F.Hoffmann-La Roche Ltd, Gilead Sciences Inc., Eli Lilly and Company, Pfizer Inc., Merck & Co. Inc., GSK plc, Celltrion Healthcare Co. Ltd, Sorrento Therapeutics, AstraZeneca plc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . COVID-19 THERAPEUTICS – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Drug Class
3.7.2 Market Attractiveness Analysis By Route Of Administration
3.7.3 Market Attractiveness Analysis By Distribution Channel
3.7.4 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
6 . GLOBAL COVID-19 THERAPEUTICS MARKET ANALYSIS BY DRUG CLASS
6.1 Overview by Drug Class
6.2 Historical and Forecast Data
6.3 Analysis by Drug Class
6.4 Corticosteroids Historic and Forecast Sales by Regions
6.5 Anti-viral Historic and Forecast Sales by Regions
6.6 Monoclonal Antibodies Historic and Forecast Sales by Regions
6.7 Kinase Inhibitors Historic and Forecast Sales by Regions
6.8 Others (Anti-inflammatory Drugs, Convalescent Plasma, Others) Historic and Forecast Sales by Regions
7 . GLOBAL COVID-19 THERAPEUTICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
7.1 Overview by Route Of Administration
7.2 Historical and Forecast Data
7.3 Analysis by Route Of Administration
7.4 Oral Historic and Forecast Sales by Regions
7.5 Parenteral Historic and Forecast Sales by Regions
8 . GLOBAL COVID-19 THERAPEUTICS MARKET SALES ANALYSIS BY DISTRIBUTION CHANNEL
8.1 Overview by Distribution Channel
8.2 Historical and Forecast Data
8.3 Analysis by Distribution Channel
8.4 Hospital Pharmacies Historic and Forecast Sales by Regions
8.5 Retail Pharmacies Historic and Forecast Sales by Regions
8.6 Online Pharmacies Historic and Forecast Sales by Regions
9 . GLOBAL COVID-19 THERAPEUTICS MARKET SALES ANALYSIS BY GEOGRAPHY
9.1. Regional Outlook Sales Analysis
9.2. Introduction Sales Analysis
9.3. North America Sales Analysis
9.3.1. Overview, Historic and Forecast Sales Analysis
9.3.2. North America By Segment Sales Analysis
9.3.3. North America By Country Sales Analysis
9.3.4. United State Sales Analysis
9.3.5. Canada Sales Analysis
9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
9.4.1. Overview, Historic and Forecast Sales Analysis
9.4.2. Europe by Segment Sales Analysis
9.4.3. Europe by Country Sales Analysis
9.4.4. United Kingdom Sales Analysis
9.4.5. France Sales Analysis
9.4.6. Germany Sales Analysis
9.4.7. Italy Sales Analysis
9.4.8. Russia Sales Analysis
9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
9.5.1. Overview, Historic and Forecast Sales Analysis
9.5.2. Asia Pacific by Segment Sales Analysis
9.5.3. Asia Pacific by Country Sales Analysis
9.5.4. China Sales Analysis
9.5.5. India Sales Analysis
9.5.6. Japan Sales Analysis
9.5.7. South Korea Sales Analysis
9.5.8. Australia Sales Analysis
9.5.9. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
9.6.1. Overview, Historic and Forecast Sales Analysis
9.6.2. Latin America by Segment Sales Analysis
9.6.3. Latin America by Country Sales Analysis
9.6.4. Brazil Sales Analysis
9.6.5. Argentina Sales Analysis
9.6.6. Peru Sales Analysis
9.6.7. Chile Sales Analysis
9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
9.7.1. Overview, Historic and Forecast Sales Analysis
9.7.2. Middle East & Africa by Segment Sales Analysis
9.7.3. Middle East & Africa by Country Sales Analysis
9.7.4. Saudi Arabia Sales Analysis
9.7.5. UAE Sales Analysis
9.7.6. Israel Sales Analysis
9.7.7. South Africa Sales Analysis
9.7.8. Rest Of Middle East And Africa Sales Analysis
10 . COMPETITIVE LANDSCAPE OF THE COVID-19 THERAPEUTICS COMPANIES
10.1. Covid-19 Therapeutics Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments
11 . COMPANY PROFILES OF COVID-19 THERAPEUTICS INDUSTRY
11.1. Top 10 Company Share Analysis
11.2. Market Concentration Rate
11.3. F.Hoffmann-La Roche Ltd
11.3.1. Company Overview
11.3.2. Company Revenue
11.3.3. Products
11.3.4. Recent Developments
11.4. Gilead Sciences Inc.
11.4.1. Company Overview
11.4.2. Company Revenue
11.4.3. Products
11.4.4. Recent Developments
11.5. Eli Lilly and Company
11.5.1. Company Overview
11.5.2. Company Revenue
11.5.3. Products
11.5.4. Recent Developments
11.6. Pfizer Inc.
11.6.1. Company Overview
11.6.2. Company Revenue
11.6.3. Products
11.6.4. Recent Developments
11.7. Merck & Co. Inc.
11.7.1. Company Overview
11.7.2. Company Revenue
11.7.3. Products
11.7.4. Recent Developments
11.8. GSK plc
11.8.1. Company Overview
11.8.2. Company Revenue
11.8.3. Products
11.8.4. Recent Developments
11.9. Celltrion Healthcare Co. Ltd
11.9.1. Company Overview
11.9.2. Company Revenue
11.9.3. Products
11.9.4. Recent Developments
11.10. Sorrento Therapeutics
11.10.1. Company Overview
11.10.2. Company Revenue
11.10.3. Products
11.10.4. Recent Developments
11.11. AstraZeneca plc.
11.11.1. Company Overview
11.11.2. Company Revenue
11.11.3. Products
11.11.4. Recent Developments
*Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
LIST OF TABLES
LIST OF FIGURES
* Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
Avail customized purchase options to meet your exact research needs: